Boston Scientific: Valuation & Growth Outlook
Boston Scientific (BSX) is rated Hold as strong organic growth and clinical momentum are offset by a valuation that already reflects much of the upside. The key question is whether…
Read the researchIndependent equity research
Stock research.
The evidence behind the view.
Company analysis, SEC filing changes and public follow-ups. Read the thesis, inspect the assumptions, and see what happened next.
Free research to read now. Premium research is coming.
Latest company analysis
New to LF0?
Three ways to start.
Understand a thesis. Compare a filing. Audit a call.
01 / Read a stock thesis
FormFactor (FORM): AI Growth vs. Valuation
FormFactor (FORM) is rated Hold as strong AI-linked demand is offset by a valuation that already prices in much of the recovery. Q1 2026 showed revenue growth, but EBITDA softened…
Read the research02 / See what changed
Comtech Telecommunications (CMTL) 10-K: MD&A Changes Lead 14 October 2026 Filing Roundup
Comtech Telecommunications (CMTL)'s MD&A section changed the most among 3 companies that filed 10-Ks on 14 October 2026, each compared against its prior-year…
Read the research03 / Check the follow-up
The Scorecard: 2 Month Update: STXS Sell — Correct so far
Revisiting our Sell call on STXS: entry $1.39, latest $1.05, -24.5%.
Read the researchFrom the research desk
Find your next read.
Company analysis
Boston Scientific: Valuation & Growth Outlook
Boston Scientific (BSX) is rated Hold as strong organic growth and clinical momentum are offset by a valuation that already reflects much of the upside. The key question is whether…
Read the researchUnusual Machines: Valuation, Cash Burn & Growth
Unusual Machines (UMAC) earns a STRONG SELL rating because the valuation already prices in a clean operating turn that cash flow has not confirmed. Revenue is growing, but heavy cash…
Read the researchStryker: Valuation, Margins & Risk
Stryker (SYK) is a HOLD as strong margins and free cash flow support the business, but the valuation already discounts much of that quality. Execution risk, including insider selling and…
Read the researchSEC filing changes
Comtech Telecommunications (CMTL) 10-K: MD&A Changes Lead 14 October 2026 Filing Roundup
Comtech Telecommunications (CMTL)'s MD&A section changed the most among 3 companies that filed 10-Ks on 14 October 2026, each compared against its prior-year…
Read the researchLunai Bioworks (LNAI) 10-K: Business Changes Lead 13 October 2026 Filing Roundup
Lunai Bioworks (LNAI)'s Business section changed the most among 10 companies that filed 10-Ks on 13 October 2026, each compared against its prior-year filing.
Read the researchHarbor Diversified 10-K: Risk Factors Changes Lead 9 October 2026 Filing Roundup
Harbor Diversified's Risk Factors section changed the most among 3 companies that filed 10-Ks on 9 October 2026, each compared against its prior-year filing.
Read the researchCall follow-ups
The Scorecard: 2 Month Update: STXS Sell — Correct so far
Revisiting our Sell call on STXS: entry $1.39, latest $1.05, -24.5%.
Read the researchThe Scorecard: 2 Month Update: NUTX Buy — Correct so far
Revisiting our Buy call on NUTX: entry $188.41, latest $200.80, +6.6%.
Read the researchThe Scorecard: 2 Month Update: LRCX Sell — Correct so far
Revisiting our Sell call on LRCX: entry $343.48, latest $277.46, -19.2%.
Read the researchLF0 Research Desk
Know how the research works.
A rating is a thesis to examine. The original analysis and later scorecard reviews let you see both the reasoning and the outcome.
Stay connected
Like the research?
Be first to hear about premium.
The current research is free to browse. The waitlist is for news about deeper premium analysis when it launches.
This form joins the LF0 premium waitlist. Substack is a separate subscription. You can read the current research without joining either.
Follow your interests
Find a company or sector.
Basic MaterialsCommunication ServicesConsumer CyclicalConsumer DefensiveEnergyFinancial ServicesHealthcareIndustrialsReal EstateTechnologyUtilities
More company research
Explore more of the company analyses featured on LF0.
- ADTRAN Holdings Stock Analysis (ADTN): Valuation, Margins, Cash Flow
- Amkor Technology: AMKR Free Cash Flow, Valuation & Customer Concentration
- Clover Health: Valuation & Margins, Cash Flow
- Eos Energy Enterprises: EOSE Cash Burn, Revenue Growth & Financing Risk
- Fluence Energy (FLNC): Backlog vs. Cash Burn
- GeneDx: Valuation, Cash Flow & Margins
- Kimbell Royalty Partners: KRP EBITDA, Leverage, Distribution Risk & Valuation
- NuScale Power: SMR Valuation, Cash Burn, Backlog & Commercialization Risk
- Remitly Global: Valuation, Growth, Margins & Cash Flow